News | Coronavirus (COVID-19) | November 18, 2020 | Dave Fornell, Editor

COVID-19 Patients With Cardiovascular Disease Have In-hospital Mortality Rates of 25 to 38 Percent

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. 


November 18, 2020 — A late-breaking study at the 2020 American Heart Association (AHA) Scientific Sessions showed nearly 20,000 patients revealed that cardiovascular disease (CVD) risk factors in COVID-19 (SARS-CoV-2) patients dramatically increased the risk of in-hospital mortality. The risk of death was particularly high for older, nonwhite men. 

To date, information on outcomes of patients hospitalized with COVID-19 has come from outside the United States or from single-institution case series, limiting the understanding in the broader community.  Earlier estimates from the first wave of COVID last spring found patients with heart disease who contracted COVID had mortality rates of 10 percent or more, and heart disease appeared to be the co-morbitity with the highest mortality rate among COVID patients. This study confirms that heart disease is a major driver for greatly increasing in-hospital mortality. 

Ann Marie Navar, M.D., Ph.D., reported she research team studied electronic health records from 54 health systems that use a COVID-19 database provided by Cerner, a health information technology firm. 

The results, measured from January to May and shared in “Impact of Cardiovascular Disease on Outcomes Among Hospitalized COVID-19 Patients: Results From >14,000 Patients Across the U.S.,” showed that in-hospital mortality ranged from 28.5 percent for patients with hypertension to 28.6 percent for those with diabetes, 25.5 percent for those with coronary artery disease, and 38.4 percent for those with heart failure.[1]

Just 1.5 percent of the patients had a stroke while hospitalized for COVID-19, but the mortality rate was 56 percent among this group. Similarly, 5 percent of patients had a heart attack, and 55.5 percent of these individuals died during their hospital stay.

In this large analysis of COVID patient hospitalized at 50+ U.S. health systems, older age, male sex, non-white race, and prior CVD or CVD risk factors conferring the higher risks for in-hospital mortality. While CVD and thrombotic complications were infrequent, those with complications had extremely high risk of death.

“These data reflect what doctors and nurses on the front lines in hospitals across the U.S. are actually seeing, where more than 1 in 15 patients hospitalized with COVID-19 does not make it home,” Navar explained. 

COVID in-hospital mortality rates by race, age and cardiovascular comorbidities.

Study results of COVID in-hospital mortality rates by race, age, sex, complications and cardiovascular comorbidities. [1]

She conducted the research at the Duke Clinical Research Institute before joining UT Southwestern as an associate professor of internal medicine and population and data sciences.

Authors: Ann Marie Navar, Duke Clinical Res Inst, Durham, NC; Robert Taylor, Stacey Purinton, Qingjiang Hou, Cerner Corp, Kansas City, MO; Eric D Peterson, Duke Clinical Res Inst, Durham, NC

Navar is a consultant for Cerner and is an uncompensated research principal investigator with the firm.
 

Related Cardiac COVID-19 Content:

COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients — Another AHA 2020 late-breaking study

VIDEO: Lingering Myocardial Involvement After COVID-19 Infection — Interview with Aaron Baggish, M.D. on AHA discussion on this topic

COVID-19 Positive STEMI Patients Have Higher Mortality 

VIDEO: How to Reduce COVID Exposure, Speed Exams and Cut Readmissions in Cardiology Departments— Interview with Keith Ellis, M.D.,

VIDEO: ECMO Hemodynamic Support Effective in Sickest COVID-19 Patients — Interview with Ryan Barbaro, M.D.

The Cardiovascular Impact of COVID-19

VIDEO: Telemedicine in Cardiology and Medical Imaging During COVID-19 — Interview with Regina Druz, M.D.

VIDEO: COVID-19 Precautions for Cardiac Imaging — Interview with Stephen Bloom, M.D.,

Find more cardiology related COVID-19 content

 

Reference: 

1.  Ann M Navar, Robert Taylor, Stacey Purinton, Qingjiang Hou and Eric D Peterson. Impact of Cardiovascular Disease on Outcomes Among Hospitalized COVID-19 Patients: Results From >14,000 Patients Across the United States. Presented at AHA 2020. Abstract 18841. Circulation. Originally published 14 Dec 2020. https://doi.org/10.1161/CIR.0000000000000940Circulation;142:e470–e500

 

 


Related Content

News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
Subscribe Now